Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT 2: Durvalumab + Monalizumab vs Durvalumab + Oleclumab in LA-NSCLC
NCT07146230Phase 2Not yet recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + Monalizumab Arm with Durvalumab + Oleclumab Arm (2 arms). Primary endpoint: Objective Response Rate observed using FDG-PET imaging at 9 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
monalizumaboleclumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07146230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146230.